Trials / Completed
CompletedNCT06127095
A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments
New perSEPtion. New Patient's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based RRMS Treatments.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 474 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to understand what the added value of natalizumab (Tysabri®) treatment is from a participant's perspective at a given time, based on a one-shot survey. The secondary objectives of the study also aim to characterize the participant's decision-making process to get the treatment; the burden of treatment, characterization of the study population, assessment of the quality of life (QoL), and fatigue dimension.
Conditions
Timeline
- Start date
- 2023-11-24
- Primary completion
- 2024-11-28
- Completion
- 2024-11-28
- First posted
- 2023-11-13
- Last updated
- 2024-12-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06127095. Inclusion in this directory is not an endorsement.